Oncology
Clinical Translational Research
Expression of c-Met in Primary and Recurrent Hepatocellular CarcinomaAsaoka Y.a · Tateishi R.b · Hayashi A.c · Ushiku T.c · Shibahara J.d · Kinoshita J.e · Ouchi Y.f · Koike M.g · Fukayama M.c · Shiina S.h · Koike K.baDepartment of Medicine, Teikyo University School of Medicine, Tokyo, Japan
bDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan cDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan dDepartment of Pathology, Kyorin University School of Medicine, Tokyo, Japan eClinical Development Center, Development Functions Unit, R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan fStatistical Analysis Group, Biometrics Department, Development Functions Unit, R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan gOncology R&D Unit, R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan hDepartment of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: October 24, 2019
Accepted: November 01, 2019
Published online: December 17, 2019
Issue release date: March 2020
Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 4
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Abstract
Background:The clinical course of hepatocellular carcinoma (HCC) is complicated, because it often recurs and shows multiple lesions, some of which progress to a more malignant form, shortening the life of the patient. The hepatocyte growth factor receptor c-Met has been shown to play an important role in the pathogenesis of HCC, but the influence of c-Met expression on the clinical course of HCC remains to be fully elucidated. Methods:We randomly selected and included 600 tumor specimens obtained from the primary and recurrent lesions of 319 HCC cases between 1995 and 2007. The expression of c-Met was determined by immunohistochemistry using archived formalin-fixed paraffin-embedded samples. We analyzed the correlation between c-Met expression and clinical parameters, including survival. In addition, we examined c-Met expression in the malignant transition of HCC in all cases including recurrent lesions. Results:Survival analysis using the multivariate Cox proportional-regression model revealed that the prognosis was significantly better in the primary cases with high c-Met expression than in those with low c-Met expression (hazard ratio 0.159, 95% confidence interval 0.065–0.391; p < 0.001). During the course of recurrence, some cases with high c-Met expression returned to low c-Met expression. Among 40 cases with high c-Met expression, 29 survived more than 2 years after detecting the high c-Met expression. Conclusion:High expression of c-Met may be a prognostic factor for a good, rather than a poor, HCC prognosis. The involvement of c-Met expression in the malignant transition of recurrent HCC is obscure.
© 2019 S. Karger AG, Basel
Related Articles:
References
-
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012.
CA Cancer J Clin . 2015;65(2):87–108.External Resources -
Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.
Jpn J Clin Oncol . 2015;45(9):884–91.External Resources -
Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, Imamura J, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C.
Hepatol Int . 2009;3(4):544–50.External Resources -
Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
Hepatology . 2006;44(6):1518–27.External Resources -
Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.
Am J Gastroenterol . 2012;107(4):569–77; quiz 578.External Resources -
Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma.
Gastroenterology . 1994;106(6):1618–24.External Resources -
Nagasue N, Kohno H, Hayashi T, Uchida M, Ono T, Yukaya H, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma.
Br J Surg . 1996;83(1):127–31.External Resources -
Liang HH, Chen MS, Peng ZW, Zhang YJ, Zhang YQ, Li JQ, et al. Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study.
Ann Surg Oncol . 2008;15(12):3484–93.External Resources -
Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al. Report of the 17th Nationwide Follow-Up Survey of Primary Liver Cancer in Japan.
Hepatol Res . 2007;37(9):676–91.External Resources -
Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer.
Nat Rev Mol Cel Biol . 2010;11(12):834–48.External Resources -
Peters S, Adjei AA. MET: a promising anticancer therapeutic target.
Nat Rev Clin Oncol . 2012;9(6):314–26.External Resources -
Huh CG, Factor VM, Sánchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair.
Proc Natl Acad Sci USA . 2004;101(13):4477–82.External Resources -
Kruitwagen HS, Arends B, Spee B, Brinkhof B, van den Ingh TS, Rutten VP, et al. Recombinant hepatocyte growth factor treatment in a canine model of congenital liver hypoplasia.
Liver Int . 2011;31(7):940–9.External Resources -
Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K, et al. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.
Biochem Biophys Res Commun . 2010;394(4):1042–6.External Resources -
Giordano S, Columbano A. Met as a therapeutic target in HCC: facts and hopes.
J Hepatol . 2014;60(2):442–52.External Resources -
Bouattour M, Raymond E, Qin S, Cheng AL, Stammberger U, Locatelli G, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.
Hepatology . 2018;67(3):1132–49.External Resources -
Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Lancet Oncol . 2013;14(1):55–63.External Resources -
Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodés J, et al. c-met mRNA overexpression in human hepatocellular carcinoma.
Hepatology . 1994;19(1):88–91.External Resources -
Kondo S, Ojima H, Tsuda H, Hashimoto J, Morizane C, Ikeda M, et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma.
Int J Clin Oncol . 2013;18(2):207–13.External Resources -
Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
Hepatology . 1997;25(4):862–6.
Article / Publication Details
Received: October 24, 2019
Accepted: November 01, 2019
Published online: December 17, 2019
Issue release date: March 2020
Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 4
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
